{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:01:58Z","timestamp":1747170118634,"version":"3.40.5"},"reference-count":111,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.revmed.2024.05.019","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:53:11Z","timestamp":1716493991000},"page":"366-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traduction et republication de\u00a0: \u00ab\u00a0Prise en charge de la maladie thromboembolique veineuse associ\u00e9e au cancer chez les populations vuln\u00e9rables\u00a0\u00bb"],"prefix":"10.1016","volume":"45","author":[{"given":"S.","family":"Laporte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fr\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Couturaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-7341","authenticated-orcid":false,"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-7338","authenticated-orcid":false,"given":"A.","family":"Benmaziane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-3010","authenticated-orcid":false,"given":"L.","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bozec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-8032","authenticated-orcid":false,"given":"F.","family":"Couturaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-9264","authenticated-orcid":false,"given":"P.","family":"Debourdeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dielenseger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Douriez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-1826","authenticated-orcid":false,"given":"A.","family":"\u00c9lias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9990","authenticated-orcid":false,"given":"O.","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"C.","family":"Fr\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-099X","authenticated-orcid":false,"given":"Y.","family":"Gaboreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-8055","authenticated-orcid":false,"given":"P.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-122X","authenticated-orcid":false,"given":"O.","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-1204","authenticated-orcid":false,"given":"A.","family":"Idbaih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-8668","authenticated-orcid":false,"given":"S.","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-7880","authenticated-orcid":false,"given":"I.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-7871","authenticated-orcid":false,"given":"D.","family":"Mayeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-0555","authenticated-orcid":false,"given":"P.","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-1558","authenticated-orcid":false,"given":"F.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5984","authenticated-orcid":false,"given":"G.","family":"Pernod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-6793","authenticated-orcid":false,"given":"P.-M.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-5815","authenticated-orcid":false,"given":"M.-\u00c8.","family":"Rouge Bugat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-8391","authenticated-orcid":false,"given":"O.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-337X","authenticated-orcid":false,"given":"J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-6936","authenticated-orcid":false,"given":"M.-A.","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.revmed.2024.05.019_bib0560","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.revmed.2024.05.019_bib0565","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.revmed.2024.05.019_bib0570","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0575","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0580","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/rth2.12036","article-title":"Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism","volume":"1","author":"Moustafa","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0585","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1055\/s-0039-1683970","article-title":"Direct oral anticoagulants or standard anticoagulant therapy in fragile patients with venous thromboembolism","volume":"3","author":"L\u00f3pez-N\u00fa\u00f1ez","year":"2019","journal-title":"TH Open"},{"issue":"20","key":"10.1016\/j.revmed.2024.05.019_bib0590","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0595","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs. dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.revmed.2024.05.019_bib0600","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.revmed.2024.05.019_bib0605","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl2","key":"10.1016\/j.revmed.2024.05.019_bib0610","first-page":"962","article-title":"Are efficacy and safety of direct oral anticoagulants modified by fragility characteristics in patients with cancer associated thrombosis (TAC)? A meta-analysis of randomized controlled trials","volume":"7","author":"Laporte","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"10.1016\/j.revmed.2024.05.019_bib0615","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2010.03986.x","article-title":"Venous thrombosis in the elderly: incidence, risk factors and risk groups","volume":"8","author":"Engbers","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0620","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.revmed.2024.05.019_bib0625","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort","volume":"126","author":"Tagalakis","year":"2013","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.revmed.2024.05.019_bib0635","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1538-7836.2008.03062.x","article-title":"The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction","volume":"6","author":"Spencer","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36469\/9822","article-title":"Competing risks analysis of cancer-associated recurrent thrombosis, major bleeds, and death in a geriatric cohort","volume":"4","author":"Brown","year":"2016","journal-title":"J Health Econ Outcomes Res"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0645","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.14783","article-title":"Prognosis in patients with cancer-associated venous thromboembolism: comparison of the RIETE-VTE and modified Ottawa score","volume":"18","author":"Pfaundler","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0650","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/rth2.12215","article-title":"Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience","volume":"3","author":"Soff","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0655","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000528606","article-title":"Comparative safety and effectiveness of direct oral anticoagulants and warfarin during chemotherapy in cancer patients with venous thromboembolism aged 75\u00a0years or older: a nationwide inpatient database study","volume":"69","author":"Iwai","year":"2023","journal-title":"Gerontology"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib0660","first-page":"1046","article-title":"Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)","volume":"91","author":"L\u00f3pez-Jim\u00e9nez","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0665","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jgs.18626","article-title":"Anticoagulation and venous thromboembolism in patients aged 90\u00a0years and older: data from the RIETE registry","volume":"72","author":"Lafaie","year":"2024","journal-title":"J Am Geriat Soc"},{"issue":"10206","key":"10.1016\/j.revmed.2024.05.019_bib0670","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: implications for clinical practice and public health","volume":"394","author":"Hoogendijk","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0675","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0680","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0685","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.chest.2022.02.027","article-title":"Frailty in patients with lung cancer: a systematic review and meta-analysis","volume":"162","author":"Komici","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0690","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1007\/s00520-021-06641-8","article-title":"The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis","volume":"30","author":"Wang","year":"2022","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib0695","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1532-5415.2012.04054.x","article-title":"Prevalence of frailty in community-dwelling older persons: a systematic review","volume":"60","author":"Collard","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.revmed.2024.05.019_bib0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers11010048","article-title":"Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management","volume":"11","author":"Scott\u00e9","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.revmed.2024.05.019_bib0705","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib0710","first-page":"912","article-title":"La fibrillation atriale du sujet \u00e2g\u00e9","volume":"70","author":"Hanon","year":"2020","journal-title":"Rev Prat"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0715","doi-asserted-by":"crossref","first-page":"103405","DOI":"10.1016\/j.retram.2023.103405","article-title":"Primary prevention of cancer-associated venous thrombosis: rationale and challenges in clinical practice","volume":"71","author":"Elalamy","year":"2023","journal-title":"Curr Res Transl Med"},{"year":"2013","author":"Anon.","series-title":"Comment rep\u00e9rer la fragilit\u00e9 en soins ambulatoires\u00a0?","key":"10.1016\/j.revmed.2024.05.019_bib0720"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0725","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1468-1331.2006.01578.x","article-title":"Relevance of 10-min delayed recall in dementia screening","volume":"14","author":"de Rotrou","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0730","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.revmed.2024.05.019_bib0735","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0740","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2014.04.002","article-title":"Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality","volume":"134","author":"K\u00f6nigsbr\u00fcgge","year":"2014","journal-title":"Thromb Res"},{"issue":"9","key":"10.1016\/j.revmed.2024.05.019_bib0745","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0750","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism.findings from the RIETE Registry","volume":"100","author":"Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"Suppl2","key":"10.1016\/j.revmed.2024.05.019_bib0755","first-page":"236","article-title":"Trends in clinical characteristics, treatment and 30-day outcomes in cancer patients with venous thromboembolism from 2001\u00a0to 2020","volume":"7","author":"Bertoletti","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2\u20133","key":"10.1016\/j.revmed.2024.05.019_bib0760","first-page":"37","article-title":"Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: a position paper from the Cancer & the Kidney International Network","volume":"2","author":"Launay-Vacher","year":"2018","journal-title":"J OncoNephrol"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0765","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17425255.2022.2045273","article-title":"The impact of advanced age on anticoagulant therapy for acute venous thromboembolism","volume":"18","author":"Lafaie","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.revmed.2024.05.019_bib0770","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/jth.12411","article-title":"Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment","volume":"11","author":"Kooiman","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.revmed.2024.05.019_bib0775","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1007\/s00520-022-07136-w","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0780","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","article-title":"Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications","volume":"20","author":"Helfer","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0785","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.revmed.2024.05.019_bib0790","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00520-012-1590-9","article-title":"Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads","volume":"20","author":"Scott\u00e9","year":"2012","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0795","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2024.05.019_bib0800","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221098717","article-title":"Venous thromboembolism in cancer patients: \u201cFrom Evidence to Care\u201d","volume":"28","author":"Salgado","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0805","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11239-016-1386-8","article-title":"A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment","volume":"42","author":"Woodruff","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib0810","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.revmed.2024.05.019_bib0815","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2021.279072","article-title":"Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial","volume":"107","author":"Becattini","year":"2022","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.revmed.2024.05.019_bib0820","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.revmed.2024.05.019_bib0825","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/jth.14837","article-title":"Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism","volume":"18","author":"Catella","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.revmed.2024.05.019_bib0830","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.3390\/curroncol28060453","article-title":"Treatment algorithm in cancer-associated thrombosis: updated Canadian Expert Consensus","volume":"28","author":"Carrier","year":"2021","journal-title":"Curr Oncol"},{"issue":"18","key":"10.1016\/j.revmed.2024.05.019_bib0835","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.05.019_bib0840","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2019.04.083","article-title":"Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry","volume":"291","author":"Murgier","year":"2019","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0845","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11239-022-02633-5","article-title":"Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry","volume":"54","author":"Murgier","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.revmed.2024.05.019_bib0850","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2020.12.020","article-title":"Recovery from acute kidney injury in patients with pulmonary embolism: a single-center study","volume":"199","author":"Murgier","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.revmed.2024.05.019_bib0855","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.acvd.2023.11.010","article-title":"Anticoagulant treatment of cancer-associated thromboembolism","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"year":"2017","author":"Anon.","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5. 0","key":"10.1016\/j.revmed.2024.05.019_bib0860"},{"issue":"17","key":"10.1016\/j.revmed.2024.05.019_bib0865","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.revmed.2024.05.019_bib0870","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0875","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514\u00a0patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0880","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0885","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2024.05.019_bib0890","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs. warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0895","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane 2nd","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib0900","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1076029614543140","article-title":"Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization","volume":"20","author":"Babilonia","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0905","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1078155216631407","article-title":"Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: a case series","volume":"23","author":"Campbell","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"10.1016\/j.revmed.2024.05.019_bib0910","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1080\/10428194.2017.1306644","article-title":"Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort","volume":"58","author":"Houghton","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0915","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1711-5","article-title":"Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen","volume":"46","author":"Htun","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"10.1016\/j.revmed.2024.05.019_bib0920","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.bmt.1704952","article-title":"Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature","volume":"35","author":"Ibrahim","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.revmed.2024.05.019_bib0925","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0930","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.revmed.2024.05.019_bib0935","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1177\/1078155220957747","article-title":"Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT)","volume":"27","author":"Lam","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.revmed.2024.05.019_bib0940","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2020.07.021","article-title":"Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia","volume":"195","author":"Lecumberri","year":"2020","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.revmed.2024.05.019_bib0945","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","article-title":"Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation","volume":"1","author":"Li","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0950","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"10.1016\/j.revmed.2024.05.019_bib0955","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ajh.26268","article-title":"Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation","volume":"96","author":"Martens","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0960","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","article-title":"Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes","volume":"44","author":"Samuelson Bannow","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib0965","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11239-020-02040-8","article-title":"PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count","volume":"49","author":"Scamuffa","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0970","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11739-021-02771-3","article-title":"Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study","volume":"17","author":"Squizzato","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib0975","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jha2.90","article-title":"Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism","volume":"1","author":"Wilson","year":"2020","journal-title":"EJHaem"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib0980","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.15748","article-title":"Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multicenter prospective cohort","volume":"20","author":"Booth","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1016\/j.revmed.2024.05.019_bib0985","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2024.05.019_bib0990","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib0995","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1538-7836.2009.03280.x","article-title":"Underweight is associated with a reduced risk of venous thromboembolism. Results from the EDITH case-control study","volume":"7","author":"Delluc","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.05.019_bib1000","doi-asserted-by":"crossref","first-page":"103989","DOI":"10.1016\/j.critrevonc.2023.103989","article-title":"Thrombosis and cachexia in cancer: two partners in crime?","volume":"186","author":"Liz-Pimenta","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib1005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","article-title":"The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)","volume":"3","author":"Barba","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib1010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/rth2.12492","article-title":"Apixaban in low-weight patients with cancer-associated thrombosis: a cross sectional study of drug levels","volume":"5","author":"Bravo Villa","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.revmed.2024.05.019_bib1015","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"25","key":"10.1016\/j.revmed.2024.05.019_bib1020","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2024.05.019_bib1025","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/jcm8122158","article-title":"Risk of venous thromboembolic events in patients with osteonecrosis of the femoral head undergoing primary hip arthroplasty","volume":"8","author":"Sung","year":"2019","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib1030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u00a0\u2013\u00a0viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.revmed.2024.05.019_bib1035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2018.5639","article-title":"Proportion of cancer cases attributable to excess body weight by US state, 2011\u20132015","volume":"5","author":"Islami","year":"2019","journal-title":"JAMA Oncol"},{"unstructured":"World Health Organization. Cancer; 2022.","key":"10.1016\/j.revmed.2024.05.019_bib1040"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib1045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"Pomp","year":"2007","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.revmed.2024.05.019_bib1050","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2024.05.019_bib1055","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2\u00a0rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"Rodger","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib1060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib1065","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/rth2.12146","article-title":"Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120\u00a0kilograms: a retrospective study","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.05.019_bib1070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2016.04.019","article-title":"Direct oral anticoagulant drug level testing in clinical practice: a single institution experience","volume":"143","author":"Martin","year":"2016","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.revmed.2024.05.019_bib1075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm10020200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity","volume":"10","author":"Cohen","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.revmed.2024.05.019_bib1080","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/a-1588-9155","article-title":"Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis","volume":"122","author":"Wang","year":"2022","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.revmed.2024.05.019_bib1085","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib1090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","article-title":"Dosage of enoxaparin among obese and renal impairment patients","volume":"116","author":"Bazinet","year":"2005","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib1095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1538-7836.2004.01053.x","article-title":"The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients","volume":"3","author":"Al-Yaseen","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.revmed.2024.05.019_bib1100","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1538-7836.2007.02565.x","article-title":"Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials","volume":"5","author":"Davidson","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.revmed.2024.05.019_bib1105","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials","volume":"101","author":"van Doormaal","year":"2009","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2024.05.019_bib0555","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in people with cancer","volume":"1","author":"Hakoum","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324005812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324005812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T02:12:37Z","timestamp":1717899157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324005812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0248866324005812"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.05.019","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traduction et republication de\u00a0: \u00ab\u00a0Prise en charge de la maladie thromboembolique veineuse associ\u00e9e au cancer chez les populations vuln\u00e9rables\u00a0\u00bb","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}